文献速递消化道肿瘤与早癌消化内镜

内镜黏膜下剥离术治疗早期胃癌后治愈性分层评分系统:「eCura系统」

A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: "eCura system".
PubMed 文献 · Am J Gastroenterol · 2017-04-11

该多中心回顾性研究分两阶段开发并内部验证eCura评分系统:在1101例ESD后未达治愈标准而接受根治性手术的患者中,基于淋巴管侵犯(3分)、肿瘤>30mm、垂直切缘阳性、静脉侵犯、黏膜下浸润≥500μm(各1分)构建淋巴结转移风险评分;低危(0-1分)2.5%、中危(2-4分)6.7%、高危(5-7分)22.7%。在905例未接受追加治疗的患者中验证,5年癌症特异生存率分别为99.6%、96.0%、90.1%(P<0.001)。

要点

  • eCura评分:淋巴管侵犯3分,肿瘤>30mm、垂直切缘阳性、静脉侵犯、黏膜下浸润≥500μm各1分。
  • 低危(0-1分)淋巴结转移风险2.5%,中危(2-4分)6.7%,高危(5-7分)22.7%。
  • 验证队列5年癌症特异生存率低危99.6%、中危96.0%、高危90.1%(P<0.001)。

核心结论

  • 该评分系统可预测ESD治疗早期胃癌后未达治愈标准患者的癌症特异生存。
  • 作者认为,低危患者不追加治疗而仅行ESD可能是可接受的选择。

研究设计与样本

  • 多中心回顾性研究,分两阶段:开发阶段纳入1101例ESD后未达治愈标准而接受根治性手术的患者,采用多变量逻辑回归分析构建淋巴结转移风险评分。
  • 验证阶段在另905例同样未达治愈标准且ESD后未接受追加治疗的患者中,通过生存分析进行内部验证。

主要发现

  • 开发阶段基于回归系数对5个淋巴结转移危险因素赋分:淋巴管侵犯3分,肿瘤大小>30mm、垂直切缘阳性、静脉侵犯、黏膜下浸润≥500μm各1分。
  • 按总分分为三组:低危(0-1分)淋巴结转移风险2.5%,中危(2-4分)6.7%,高危(5-7分)22.7%。
  • 验证阶段三组5年癌症特异生存率分别为低危99.6%、中危96.0%、高危90.1%,差异有统计学意义(P<0.001)。
  • 该系统预测癌症特异死亡的C统计量为0.78。

关键数值与推荐

  • 淋巴管侵犯赋3分;肿瘤大小>30mm、垂直切缘阳性、静脉侵犯、黏膜下浸润≥500μm各赋1分。
  • 低危0-1分,淋巴结转移风险2.5%;中危2-4分,风险6.7%;高危5-7分,风险22.7%。
  • 验证队列5年癌症特异生存率:低危99.6%、中危96.0%、高危90.1%(P<0.001)。
  • 预测癌症特异死亡的C统计量为0.78。

临床怎么用

  • 作者认为,ESD后未达治愈标准的低危患者不追加治疗而仅行ESD可能是可接受的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although radical surgery is recommended for patients not meeting the curative criteria for endoscopic submucosal dissection (ESD) of early gastric cancer (EGC) because of the potential risk of lymph node metastasis (LNM), this recommendation may be overestimated and excessive. We aimed to establish a simple scoring system for decision making after ESD. METHODS: This multicenter retrospective study consisted of two stages. First, the risk-scoring system for LNM was developed using multivariate logistic regression analysis in 1,101 patients who underwent radical surgery after having failed to meet the curative criteria for ESD of EGC. Next, the system was internally validated by survival analysis in another 905 patients who also did not meet the criteria and did not receive additional treatment after ESD. RESULTS: In the development stage, based on accordant regression coefficients, five risk factors for LNM were weighted with point values: three points for lymphatic invasion and 1 point each for tumor size >30 mm, positive vertical margin, venous invasion, and submucosal invasion ≥500 μm. Then, the patients were categorized into three LNM risk groups: low (0-1 point: 2.5% risk), intermediate (2-4 points: 6.7%), and high (5-7 points: 22.7%). In the validation stage, cancer-specific survival differed significantly among these groups (99.6, 96.0, and 90.1%, respectively, at 5 years; P<0.001). The C statistic of the system for cancer-specific mortality was 0.78. CONCLUSIONS: This scoring system predicted cancer-specific survival in patients who did not meet the curative criteria after ESD for EGC. ESD without additional treatment may be an acceptable option for patients at low risk.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hatta W, Gotoda T, Oyama T, et al. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: "eCura system". Am J Gastroenterol. 2017. PMID: 28397873. doi:10.1038/ajg.2017.95

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。